Evidence map›Paper›PMID 41366188›Full record

ArticleInternational journal of hematology2026

Central nervous system involvement in plasma cell neoplasms: a rare presentation illustrated by three cases.

Hiroki Tsutsumi, Naoko Inoshita, Noriaki Tanabe, Yasunobu Sekiguchi, Hiroaki Kanda

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hiroki TsutsumiDepartment of Hematology, Saitama Cancer Center, Saitama, Japan. HTsutsumi@mdanderson.org.ORCID http://orcid.org/0000-0001-8852-9328
Naoko InoshitaDepartment of Pathology, Saitama Cancer Center, Saitama, Japan.
Noriaki TanabeDepartment of Pathology, Saitama Cancer Center, Saitama, Japan.
Yasunobu SekiguchiDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.
Hiroaki KandaDepartment of Pathology, Saitama Cancer Center, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system (CNS) involvement in plasma cell neoplasms is rare and associated with poor prognosis, and indications for cerebrospinal fluid (CSF) analysis remain undefined. We describe three cases: two with advanced-stage, high-risk cytogenetics, and one stage I case meeting criteria for plasma cell leukemia (PCL). In two patients, delayed CSF evaluation after neurological symptoms led to rapid deterioration, whereas early CSF analysis in an asymptomatic patient enabled timely diagnosis. One case worsened acutely after treatment with plerixafor. These findings suggest that CSF evaluation may merit consideration in high-risk patients, including those with PCL or before plerixafor administration.

Indexed as

Central Nervous System NeoplasmsLeukemia, Plasma CellNeoplasms, Plasma CellAgedBenzylaminesCyclamsFemaleHumansMaleMiddle AgedBenzylaminesCyclamsplerixaforCNSMultiple myelomaPlasma cell neoplasma

Identifiers

PMID41366188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.